CVS Caremark will replace branded bone disease drugs with lower cost biosimilars starting in April
CVS Health will replace branded bone disease treatments with cheaper biosimilars on April 1. This shift is expected to reduce drug costs by over 50 percent.
Insights:
Caremark, the pharmacy benefit management unit of CVS Health Corporation , announced today that it will replace the branded bone-disease treatments Prolia, manufactured by Amgen Inc. , and Forteo, produced by Eli Lilly and Company , with lower-cost biosimilars and generics on certain preferred drug lists. This transition is scheduled to take effect on April 1, 2026, across the US 
US. The decision is intended to reduce per-prescription costs by more than 50% compared to the branded versions of these medications.
US. The decision is intended to reduce per-prescription costs by more than 50% compared to the branded versions of these medications.
